Cargando…

Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death

AIMS: Catecholaminergic polymorphic ventricular tachycardia (CPVT) and short QT syndrome (SQTS) are inherited arrhythmogenic disorders that can cause sudden death. Numerous genes have been reported to cause these conditions, but evidence supporting these gene–disease relationships varies considerabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walsh, Roddy, Adler, Arnon, Amin, Ahmad S, Abiusi, Emanuela, Care, Melanie, Bikker, Hennie, Amenta, Simona, Feilotter, Harriet, Nannenberg, Eline A, Mazzarotto, Francesco, Trevisan, Valentina, Garcia, John, Hershberger, Ray E, Perez, Marco V, Sturm, Amy C, Ware, James S, Zareba, Wojciech, Novelli, Valeria, Wilde, Arthur A M, Gollob, Michael H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009401/ https://www.ncbi.nlm.nih.gov/pubmed/34557911 http://dx.doi.org/10.1093/eurheartj/ehab687

Ejemplares similares

An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome
por: Adler, Arnon, et al.
Publicado: (2020)

Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome
por: Hosseini, S. Mohsen, et al.
Publicado: (2018)

Recurrent and Founder Mutations in the Netherlands: the Long-QT Syndrome
por: Hofman, N., et al.
Publicado: (2010)

Echocardiography-Guided Arrhythmic Risk Prediction in the Long QT Syndrome
por: Agarwal, Rakesh, et al.
Publicado: (2021)

Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations
por: Novak, Atara, et al.
Publicado: (2015)

Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3
por: Mazzanti, Andrea, et al.
Publicado: (2016)

QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
por: Sridhar, Arun R., et al.
Publicado: (2020)

Arrhythmic risk during pregnancy and postpartum in patients with long QT syndrome
por: Asatryan, Babken, et al.
Publicado: (2021)

The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT
por: Blackwell, Daniel J., et al.
Publicado: (2022)

CPVT and Complete Atrio-Ventricular Block: The Flipside of the Same Coin
por: Petrungaro, Mattia, et al.
Publicado: (2023)

Association of QT dispersion with mortality and arrhythmic events—A meta‐analysis of observational studies
por: Bazoukis, George, et al.
Publicado: (2019)

COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias
por: Crotti, Lia, et al.
Publicado: (2020)

Pro-arrhythmic effects of gain-of-function potassium channel mutations in the short QT syndrome
por: Hancox, J. C., et al.
Publicado: (2023)

CPVT: Arrhythmogenesis, Therapeutic Management, and Future Perspectives. A Brief Review of the Literature
por: Baltogiannis, Giannis G., et al.
Publicado: (2019)

Editorial to “Association of QT dispersion with mortality and arrhythmic events—A meta‐analysis of observational studies”
por: Karadeniz, Cem
Publicado: (2019)

Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations
por: Uzelac, Ilija, et al.
Publicado: (2021)

Beyond gene-disease validity: capturing structured data on inheritance, allelic-requirement, disease-relevant variant classes, and disease mechanism for inherited cardiac conditions
por: Josephs, Katherine S, et al.
Publicado: (2023)

Beyond gene-disease validity: capturing structured data on inheritance, allelic requirement, disease-relevant variant classes, and disease mechanism for inherited cardiac conditions
por: Josephs, Katherine S., et al.
Publicado: (2023)

Catecholaminergic polymorphic ventricular tachycardia patients with multiple genetic variants in the PACES CPVT Registry
por: Roston, Thomas M., et al.
Publicado: (2018)

Molecular Changes in the Cardiac RyR2 With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
por: Dulhunty, Angela F.
Publicado: (2022)

Deadly emotional argument: Sudden cardiac death in catecholaminergic polymorphic ventricular tachycardia (CPVT)
por: Violano, Michele, et al.
Publicado: (2022)

Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
por: Cipriani, Alberto, et al.
Publicado: (2020)

Artificial Intelligence ECG Analysis in Patients with Short QT Syndrome to Predict Life-Threatening Arrhythmic Events
por: Pasero, Eros, et al.
Publicado: (2023)

Do CPVT-linked mutations alter RYR2 regulation by cytosolic Ca(2+) in cardiomyocytes?
por: Yamaguchi, Naohiro
Publicado: (2022)

TECRL, a new life‐threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT
por: Devalla, Harsha D, et al.
Publicado: (2016)

COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm
por: Gollob, Michael H.
Publicado: (2020)

Enhancing the interpretation of genetic observations in KCNQ1 in unselected populations: relevance to secondary findings
por: Novelli, Valeria, et al.
Publicado: (2023)

Cardiomyocytes generated from CPVT(D307H) patients are arrhythmogenic in response to β-adrenergic stimulation
por: Novak, Atara, et al.
Publicado: (2012)

The oxidation‐resistant CaMKII‐MM281/282VV mutation does not prevent arrhythmias in CPVT1
por: Sadredini, Mani, et al.
Publicado: (2021)

Trigger vs. Substrate: Multi-Dimensional Modulation of QT-Prolongation Associated Arrhythmic Dynamics by a hERG Channel Activator
por: Colman, Michael A., et al.
Publicado: (2017)

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020)

Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform
por: Visone, Roberta, et al.
Publicado: (2022)

The Measurement of the QT Interval
por: Postema, Pieter G, et al.
Publicado: (2014)

Genotype- and Sex-Specific QT-RR Relationship in the Type-1 Long-QT Syndrome
por: Couderc, Jean-Philippe, et al.
Publicado: (2012)

Which QT Correction Formulae to Use for QT Monitoring?
por: Vandenberk, Bert, et al.
Publicado: (2016)

Omega-3 Fatty Acids: Anti-Arrhythmic, Pro-Arrhythmic, or Both?
por: von Schacky, C.
Publicado: (2012)

Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios in patients with primary hyperparathyroidism and their relationship with cardiac arrhythmic events
por: YILMAZ, Yücel, et al.
Publicado: (2021)

Treatment of the arrhythmic storm
por: Grieco, Domenico, et al.
Publicado: (2019)

Risk stratifiers for arrhythmic and non-arrhythmic mortality after acute myocardial infarction
por: Gañán-Calvo, Alfonso M., et al.
Publicado: (2018)

Mitochondrial Dysfunction Increases Arrhythmic Triggers and Substrates; Potential Anti-arrhythmic Pharmacological Targets
por: Saadeh, Khalil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5r8o337qlnb65dlqi12a29urbu